Redx Pharma Plc (Redx Pharma), formerly Redx Pharma Ltd is a drug discovery and development company that develops early stage and small molecule therapeutics. The company’s major pipeline products include RXC004, RXC007, RXC008, DDR, RXC006/AZD5055, JZP815, among other drug candidates. Its drug products are used for the treatment of pancreatic cancer, idiopathic pulmonary fibrosis (IPF), fibro stenotic crohn’s disease, oncology and fibrosis, and Fibrosis, Cancer-associated fibrosis. Redx Pharma’s redox switch is also used for delivering multiple development candidates over mechanistic approaches in the treatment of cancer. The company conducts research through its facilities in the UK. Redx Pharma is headquartered in Macclesfield, the UK.
Headquarters
United Kingdom
Address
Block 33, Mereside, Alderley Park, Macclesfield, Cheshire, SK104TG
Website
www.redxpharma.com
Telephone
44 1625 469900
No of Employees
101
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
REDX (LON)
Revenue (2022)
$5.2M
-77.5%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-84.1%
(2022 vs 2021)
Market Cap*
$44.8M
Net Profit Margin (2022)
XYZ
-719.1%
(2022 vs 2021)
* As of and is in US$
Products and Services
| Products |
|---|
| Pipeline |
| ROCK2 Selective Inhibitor |
| zelasudil (RXC007) |
| XYZ |
| XYZ |
| XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2023 | Others | In April, the company and Jounce Therapeutics Inc terminated their plans to merge. |
| 2023 | Contracts/Agreements | In February, the company and Jounce Therapeutics Inc agreed to merge and form Redx Inc for the treatment of cancer and fibrotic diseases. |
| 2022 | Contracts/Agreements | In December, the company entered into a clinical trial collaboration and supply agreement with Merck for the supply of KEYTRUDA. |
Competitor Comparison
| Key Parameters | Redx Pharma Plc | Ergomed Plc | ORION Clinical Services Ltd | Proteome Sciences Plc | e-Therapeutics Plc |
|---|---|---|---|---|---|
| Headquarters | United Kingdom | United Kingdom | United Kingdom | United Kingdom | United Kingdom |
| City | Macclesfield | Guildford | Slough | Addlestone | London |
| State/Province | Cheshire | England | England | England | England |
| No. of Employees | 101 | 1,437 | 117 | 29 | 38 |
| Entity Type | Public | Private | Private | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Lisa Anson | Chief Executive Officer; Director | Executive Board | 2018 | - |
| Peter Collum | Chief Financial Officer | Senior Management | 2021 | - |
| James Mead | Chief Operating Officer | Senior Management | 2021 | - |
| Jane Robertson | Chief Medical Officer | Senior Management | 2021 | - |
| Richard Armer | Chief Scientific Officer | Senior Management | 2014 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer